Daewon Pharmaceutical Co. Ltd. (003220) - Net Assets
Based on the latest financial reports, Daewon Pharmaceutical Co. Ltd. (003220) has net assets worth ₩270.98 Billion KRW (≈ $183.64 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩595.99 Billion ≈ $403.89 Million USD) and total liabilities (₩325.01 Billion ≈ $220.26 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore 003220 net asset momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩270.98 Billion |
| % of Total Assets | 45.47% |
| Annual Growth Rate | 7.19% |
| 5-Year Change | 25.72% |
| 10-Year Change | 69.48% |
| Growth Volatility | 4.21 |
Daewon Pharmaceutical Co. Ltd. - Net Assets Trend (2011–2025)
This chart illustrates how Daewon Pharmaceutical Co. Ltd.'s net assets have evolved over time, based on quarterly financial data. Check 003220 PP&E to net assets ratio to assess the company's strategic physical and investment asset allocation.
Annual Net Assets for Daewon Pharmaceutical Co. Ltd. (2011–2025)
The table below shows the annual net assets of Daewon Pharmaceutical Co. Ltd. from 2011 to 2025. For live market cap and overall valuation, see 003220 stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | ₩274.58 Billion ≈ $186.08 Million |
-3.51% |
| 2024-12-31 | ₩284.58 Billion ≈ $192.85 Million |
+7.69% |
| 2023-12-31 | ₩264.26 Billion ≈ $179.09 Million |
+6.23% |
| 2022-12-31 | ₩248.77 Billion ≈ $168.58 Million |
+13.90% |
| 2021-12-31 | ₩218.40 Billion ≈ $148.01 Million |
+2.65% |
| 2020-12-31 | ₩212.77 Billion ≈ $144.19 Million |
+4.19% |
| 2019-12-31 | ₩204.22 Billion ≈ $138.39 Million |
+11.47% |
| 2018-12-31 | ₩183.20 Billion ≈ $124.15 Million |
+8.96% |
| 2017-12-31 | ₩168.13 Billion ≈ $113.94 Million |
+3.78% |
| 2016-12-31 | ₩162.01 Billion ≈ $109.79 Million |
+8.98% |
| 2015-12-31 | ₩148.66 Billion ≈ $100.75 Million |
+10.52% |
| 2014-12-31 | ₩134.51 Billion ≈ $91.16 Million |
+9.14% |
| 2013-12-31 | ₩123.25 Billion ≈ $83.53 Million |
+9.14% |
| 2012-12-31 | ₩112.92 Billion ≈ $76.53 Million |
+8.67% |
| 2011-12-31 | ₩103.92 Billion ≈ $70.42 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Daewon Pharmaceutical Co. Ltd.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 25140664812000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩251.41 Billion | 94.54% |
| Other Components | ₩14.51 Billion | 5.46% |
| Total Equity | ₩265.92 Billion | 100.00% |
Daewon Pharmaceutical Co. Ltd. Competitors by Market Cap
The table below lists competitors of Daewon Pharmaceutical Co. Ltd. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
RTX A/S
CO:RTX
|
$115.62 Million |
|
Patria Bank SA
RO:PBK
|
$115.63 Million |
|
Khonburi Sugar Public Company Limited
BK:KBS
|
$115.63 Million |
|
Hurco Companies Inc
NASDAQ:HURC
|
$115.65 Million |
|
DEVEX Resources Ltd
AU:DEV
|
$115.60 Million |
|
GCL NEW ENERGY HD-0832
F:TJI
|
$115.58 Million |
|
Caisse Regionale de Credit Agricole Mutuel Loire HauteLoire
PA:CRLO
|
$115.56 Million |
|
Orian Sh.M. Ltd
TA:ORIN
|
$115.39 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Daewon Pharmaceutical Co. Ltd.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 275,284,566,430 to 265,918,340,220, a change of -9,366,226,210 (-3.4%).
- Net loss of 1,379,677,420 reduced equity.
- Dividend payments of 6,430,031,700 reduced retained earnings.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-1.38 Billion | -0.52% |
| Dividends Paid | ₩6.43 Billion | -2.42% |
| Other Changes | ₩-1.56 Billion | -0.59% |
| Total Change | ₩- | -3.40% |
Book Value vs Market Value Analysis
This analysis compares Daewon Pharmaceutical Co. Ltd.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.64x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 0.99x to 0.64x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | ₩8019.68 | ₩7960.00 | x |
| 2018-12-31 | ₩8761.74 | ₩7960.00 | x |
| 2019-12-31 | ₩9785.93 | ₩7960.00 | x |
| 2020-12-31 | ₩10382.50 | ₩7960.00 | x |
| 2021-12-31 | ₩10335.27 | ₩7960.00 | x |
| 2022-12-31 | ₩11966.66 | ₩7960.00 | x |
| 2023-12-31 | ₩12558.89 | ₩7960.00 | x |
| 2024-12-31 | ₩12843.70 | ₩7960.00 | x |
| 2025-12-31 | ₩12406.70 | ₩7960.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Daewon Pharmaceutical Co. Ltd. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -0.52%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -0.23%
- • Asset Turnover: 0.99x
- • Equity Multiplier: 2.31x
- Recent ROE (-0.52%) is below the historical average (8.96%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 9.10% | 6.79% | 0.99x | 1.35x | ₩-937.14 Million |
| 2012 | 8.55% | 6.96% | 0.94x | 1.31x | ₩-1.62 Billion |
| 2013 | 10.06% | 7.75% | 0.99x | 1.31x | ₩69.83 Million |
| 2014 | 11.75% | 8.64% | 1.01x | 1.35x | ₩2.34 Billion |
| 2015 | 11.94% | 8.19% | 1.11x | 1.31x | ₩2.88 Billion |
| 2016 | 12.54% | 8.41% | 1.12x | 1.33x | ₩4.10 Billion |
| 2017 | 6.39% | 4.05% | 1.17x | 1.35x | ₩-6.06 Billion |
| 2018 | 12.94% | 8.28% | 1.04x | 1.50x | ₩5.39 Billion |
| 2019 | 13.32% | 8.59% | 0.97x | 1.60x | ₩6.79 Billion |
| 2020 | 8.25% | 5.72% | 0.92x | 1.57x | ₩-3.75 Billion |
| 2021 | 3.19% | 1.97% | 0.82x | 1.96x | ₩-14.94 Billion |
| 2022 | 12.73% | 6.67% | 1.06x | 1.81x | ₩6.85 Billion |
| 2023 | 8.98% | 4.54% | 1.04x | 1.91x | ₩-2.70 Billion |
| 2024 | 5.16% | 2.38% | 1.03x | 2.12x | ₩-13.32 Billion |
| 2025 | -0.52% | -0.23% | 0.99x | 2.31x | ₩-27.97 Billion |
Industry Comparison
This section compares Daewon Pharmaceutical Co. Ltd.'s net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $471,807,173,917
- Average return on equity (ROE) among peers: 4.30%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Daewon Pharmaceutical Co. Ltd. (003220) | ₩270.98 Billion | 9.10% | 1.20x | $115.62 Million |
| Dongwha Pharm.Co.Ltd (000020) | $227.23 Billion | 0.45% | 0.39x | $99.74 Million |
| Yuhan Corp. (000100) | $1.12 Trillion | 8.27% | 0.18x | $4.18 Billion |
| Yuhan Corp Preferred (000105) | $1.94 Trillion | 5.30% | 0.27x | $45.29 Million |
| Yuyu Pharma (000220) | $78.29 Billion | 7.52% | 0.42x | $41.89 Million |
| Yuyu Pharma Inc (000225) | $78.29 Billion | 7.52% | 0.42x | $14.63 Million |
| Yuyu Pharma Inc (000227) | $78.29 Billion | 7.52% | 0.42x | $30.97 Million |
| Ildong Holdings Co Ltd (000230) | $164.95 Billion | -2.25% | 0.61x | $50.99 Million |
| Samil Pharm (000520) | $65.75 Billion | -8.13% | 2.44x | $97.26 Million |
| Donga Socio Holdings (000640) | $746.90 Billion | 2.65% | 0.82x | $405.77 Million |
| Jw Pharmac (001060) | $225.76 Billion | 14.13% | 1.78x | $440.87 Million |
About Daewon Pharmaceutical Co. Ltd.
Daewon Pharmaceutical Co., Ltd., a pharmaceutical company, manufactures and sells medicines and medical supplies in South Korea. It offers various medicines for circulatory, respiratory, antibiotic, chemotherapy, and psychoneurosis use. The company's principal products include Oramin-F Soft Cap, a multivitamin product; Pelubi Tablet, a NSAID product for pain relief; Freefol-MCT Inj., a microemuls… Read more